Fate Therapeutics Appoints New CMO and CSO
Ticker: FATE · Form: 8-K · Filed: Jul 31, 2024 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | 8-K |
| Filed Date | Jul 31, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-appointment, biotech
TL;DR
Fate Therapeutics beefs up leadership with new CMO & CSO appointments.
AI Summary
On July 29, 2024, Fate Therapeutics, Inc. announced the appointment of Dr. Nicole A. Shuman as Chief Medical Officer and Dr. Jeffrey S. W. Smith as Chief Scientific Officer. Dr. Shuman previously served as Senior Vice President of Clinical Development, and Dr. Smith was Senior Vice President of Research and Development. The company also reported on compensatory arrangements for these newly appointed officers.
Why It Matters
The appointment of key leadership roles in Chief Medical Officer and Chief Scientific Officer positions signals a strategic shift or reinforcement of the company's direction in research and development, potentially impacting its pipeline and future clinical trials.
Risk Assessment
Risk Level: medium — Leadership changes in critical scientific and medical roles can indicate strategic shifts or challenges within a biotech company, warranting closer scrutiny.
Key Players & Entities
- Fate Therapeutics, Inc. (company) — Registrant
- Dr. Nicole A. Shuman (person) — Appointed Chief Medical Officer
- Dr. Jeffrey S. W. Smith (person) — Appointed Chief Scientific Officer
- July 29, 2024 (date) — Date of earliest event reported
FAQ
What were the previous roles of Dr. Nicole A. Shuman and Dr. Jeffrey S. W. Smith?
Dr. Nicole A. Shuman previously served as Senior Vice President of Clinical Development, and Dr. Jeffrey S. W. Smith was Senior Vice President of Research and Development.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on July 29, 2024.
What is the principal executive office address for Fate Therapeutics, Inc.?
The principal executive office is located at 12278 Scripps Summit Dr., San Diego, CA 92131.
What is the SIC code for Fate Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).
What specific items are covered in this 8-K filing?
This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD Disclosure, and Financial Statements and Exhibits.
Filing Stats: 982 words · 4 min read · ~3 pages · Grade level 10.1 · Accepted 2024-07-31 16:03:29
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share FATE The Nasdaq
Filing Documents
- d764342d8k.htm (8-K) — 30KB
- d764342dex991.htm (EX-99.1) — 13KB
- g764342g0731010924611.jpg (GRAPHIC) — 4KB
- 0001193125-24-189911.txt ( ) — 171KB
- fate-20240729.xsd (EX-101.SCH) — 3KB
- fate-20240729_lab.xml (EX-101.LAB) — 17KB
- fate-20240729_pre.xml (EX-101.PRE) — 11KB
- d764342d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press release dated July 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 31, 2024 Fate Therapeutics, Inc. By: /s/ J. Scott Wolchko J. Scott Wolchko President and Chief Executive Officer